April 11, 2025
American Fertility Tech Startup illumicell AI Raises $2M USD in Pre-Seed Round To Advance Real-Time Male Diagnostics
Allston, Massachusetts, United States –
illumicell AI, focused on revolutionizing fertility care using AIhas secured $2M USD in pre-seed funding to accelerate development of its AI-powered fertility care platform. The round, announced on April 10, 2025, was backed by investors including Dr. Jeremy Teoh, KOFA Healthcare, and MedTech Syndicates. The funding aims to support the company’s mission of making male fertility testing faster, more accurate, and accessible globally.
About illumicell AI
Founded in 2023 by Harvard-trained physician Dr. Michel Bielecki, ex-McKinsey consultant Jeyla Sadikova, and aerospace engineer Loup Cordey, illumicell AI is building a portable lab scanner and real-time AI platform capable of analyzing cells and biomarkers within minutes. The technology targets male reproductive health—an area traditionally underserved despite the fact that 1 in 6 couples face infertility and less than 25% of men undergo proper evaluation. illumicell AI's platform is revolutionizing male fertility diagnostics by enabling clinical-grade, real-time testing at the point of care. With a dataset of over 400,000 datapoints, each scan contributes structured, labeled information that can help track supplement responses, lifestyle-linked changes, and early fertility decline. While the current focus is on semen analysis, the underlying technology is designed to expand to other bodily fluids such as urine and cerebrospinal fluid, offering broader utility in fluid-based diagnostics.
Purpose of financing
The newly raised capital will be used to advance product development, support ongoing clinical trials, and prepare for FDA submission by 2026. The company also aims to grow its engineering and clinical teams, as it moves toward commercialization and regulatory milestones.
Founder’s Insights
Jeyla Sadikova, co-founder and Chief Science Officer of illumicell AI, stated:
“Up to half of all cases of infertility involve male factors, but the fertility burden remains almost entirely on women: a bias that’s both culturally driven and scientifically flawed. That’s why we’re making fast, accurate, scalable male fertility diagnostics accessible anywhere, so diagnosis starts where it should: with both partners, equally.”
Dr. Michel Bielecki, co-founder and CEO, added:
“Semen diagnostics are a massive inefficiency within the medical system. Our real-time, lab-grade fluid diagnostics reduce wait times and cost, radically improving the quality of healthcare across the board.”
Investor Perspective
Dr. Jeremy Teoh, urologist and investor, added:
“As a clinician, this is a game changer. illumicell AI brings sperm testing into the era of AI: real-time, clinical-grade results, without outsourcing or delays.”
Conclusion
With a bold mission to democratize access to fertility care, illumicell AI is poised to reshape how male infertility is diagnosed and addressed, making diagnostics faster, cheaper, and more inclusive.
For updates, visit illumicell AI on LinkedIn.